About Brabant Pharma
Brabant Pharma is a company based in San Francisco (United States) founded in 2013 was acquired by Zogenix in October 2014. Brabant Pharma offers products and services including emPura, Sông Lam Oil, Hupavir Sinecatechin, and Myovit 3. Brabant Pharma operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Brabant Pharma
Brabant Pharma offers a comprehensive portfolio of products and services, including emPura, Sông Lam Oil, Hupavir Sinecatechin, and Myovit 3.
Foam for intimate hygiene and cleaning based on safety standards
Oil for reducing joint pain and inflammation
Capsules for immune support and health maintenance
Eye drop solution for relieving discomfort and irritation
Funding Insights of Brabant Pharma
Investors in Brabant Pharma
Brabant Pharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Zogenix and Aquarius Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Science focused VC firm investing in the US & UK
|
Locked | Locked | Locked | |
|
Drug delivery systems for CNS disorders and pain are developed.
|
Locked | Locked | Locked |
Investor details for Brabant Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Brabant Pharma
Investment portfolio details for Brabant Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Brabant Pharma
Detailed financials for Brabant Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Brabant Pharma Comparisons
Peer comparison for Brabant Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Brabant Pharma
Brabant Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
|
| Locked | Locked | Locked |
Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema.
|
Detailed competitors of Brabant Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Brabant Pharma
Complete news archive for Brabant Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brabant Pharma
Brabant Pharma was founded in 2013.
Brabant Pharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Brabant Pharma was founded in 2013 in San Francisco, United States, with a focus on therapeutics for rare central nervous system disorders. The lead product, Brabafen, a low-dose fenfluramine formulation, was advanced to Phase 3 trials for pediatric Dravet Syndrome, a severe epilepsy form. Orphan drug status was obtained from U.S. and European regulators. Acquisition by Zogenix was completed in October 2014.
Brabant Pharma's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
Brabant Pharma offers emPura, Sông Lam Oil, Hupavir Sinecatechin, and Myovit 3.
Brabant Pharma has 2 investors. Key investors include Zogenix, and Aquarius Equity Partners.